XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Objective: To compare serum estradiol (E2) level in Thai surgical menopausal women before and after receiving a daily
dose of 1 mg oral micronized 17 β -estradiol.
Design: Experimental study (before and after treatment).
Setting: Gynecological ward, Hatyai regional hospital.
Patients: 40 premenopausal Thai women who had undergone total abdominal hysterectomy with bilateral salpingoooporectomy (Surgical menopause) for 1 week previously due to benign gynecologic conditions were recruited in the present study. These women had no contraindications for receiving hormonal replacement therapy and no history of any
hormonal intake in the past.
Intervention: All women were assigned to receive a 1 mg micronized 17 β -estradiol (Estrofem , Novo Nordisk A/S,
Denmark) orally applied at bedtime (08.00 p.m.) each day.
Measurements: Serum estradiol (E2) levels were measured before and after treatment at 4, 8 and 12 weeks. The hormonal
measurement was performed using the ELFA-technique (Enzyme Linked Fluorescent Assay).
Results: Four cases were excluded due to loss to follow up. Of the remaining 36 cases, the mean age (+ SD) and the body
mass index were 46.27 + 5.74 years and 23.72 + 2.92 kg/m2, respectively. Serum E2 level significantly increased from baseline value at 4, 8 and 12 weeks (mean (+ SD) of E2 level at 0, 4, 8 and 12 weeks : 3.82 + 6.30 pg/ml, 117.11 + 92.86
pg/ml, 135.28 + 91.38 pg/ml and 164.48 + 78.94 pg/ml, p < 0.05) respectively.
Conclusion: A daily dose of 1 mg oral micronized 17 β-estradiol for 12 weeks increased the serum E2 level to the follicular
phase level of the normal menstrual cycle.
Keywords: Micronized 17 β -estradiol, Serum estradiol, Surgical menopause